PatrickS W, SchumacherR E, BenneyworthB D, KransE E, McAllisterJ M and DavisM M. 2012. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA., 307(18): 1934–1940.
2.
JonesH E, KaltenbachKHeilS H. 2010. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med., 363(24): 2320–2331.
3.
LundI O, FischerGWelle-StrandG K. 2013. A comparison of buprenorphine +naloxone to buprenorphine and methadone in the treatment of opioid dependence during regnancy: maternal and neonatal outcomes. Subst Abuse., 7: 61–74.
4.
JonesH E. 2013. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abus., 34(2): 89–91.
5.
JanisseJ J, BaileyB A, AgerJ and SokolR J. 2014. Alcohol, tobacco, cocaine, and marijuana use: relative contributions to preterm delivery and fetal growth restriction. Subst Abuse, 35(1): 60–67.
6.
SmithL M, LaGasseL LDeraufC. 2006. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics., 118(3): 1149–1156.
7.
KiblawiZ N, SmithL MDiazS D. 2014. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abuse, 35(1): 68–73.
8.
MessaadiN, PansuA, EvezardH, DebrabantS, DeruelleP and CottencinO. 2014. The continued care of pregnant women receiving opiate substitution treatment by midwives. Subst Abuse., 35(1): 56–59.
